Regenxbio (NASDAQ: RGNX) reported Q1 EPS of $0.12, $0.36 worse than the analyst estimate of $0.48. Revenue for the quarter came in at $89.01 million versus the consensus estimate of $107.85 million.

FINANCIAL GUIDANCE
REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $272.7 million as of March 31, 2025 to fund its operations into the second half of 2026. This cash runway guidance is based on the Company\'s current operational plans and excludes the impact of any material payments that may potentially be received from partners or licensees upon the achievement of development or regulatory milestones, or upon the approval or commercialization of product candidates, and excludes potential monetization of a PRV that would be received upon potential approval of clemidsogene lanparvovec.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.